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Abstract
Introduction: Idiopathic (immune) thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by low platelet counts and
bleeding episodes. Current therapy options are associated with unwanted side effects, and although patients initially respond to
treatment the platelet count is not sustained in many individuals. There is a need for safe and well-tolerated treatments that provide a
sustained platelet response. 
Aims: This review summarizes the emerging evidence for the potential use of eltrombopag in the treatment of ITP in adults.
Disease and treatment: Eltrombopag is a nonpeptide, small molecular weight thrombopoietin receptor agonist that is orally
administered. It mimics the activity of thrombopoietin, a cytokine that promotes growth and production of platelets, primarily inducing
proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.
Profile: Eltrombopag is still in the early stages of development but initial phase I and phase II results are promising. Potential advantages
of eltrombopag may include a sustained platelet response and a good tolerability profile. Its once-daily oral dosing regimen would also
be an advantage over many of the existing therapies. It is expected that patients who have failed first-line therapy with corticosteroids
and wish to avoid the need for a splenectomy, and patients with chronic refractory ITP, may benefit from eltrombopag treatment.
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Core emerging evidence summary for eltrombopag in ITP
Outcome measure Emerging evidence
Patient-oriented evidence
Tolerability  Good tolerability in healthy volunteers
Convenience of administration Oral, once-daily dosing
Disease-oriented evidence
Platelet response Dose-dependent increase in platelet count at doses of 30 mg and above
Safety  Does not induce platelet activation or enhance agonist-induced platelet aggregation
Specificity Specific for human/chimpanzee thrombopoietin receptorScope, aims, and objectives
Eltrombopag (SB497115; GlaxoSmithKline & Ligand
Pharmaceuticals Inc) is an oral thrombopoietin agonist in
development for the treatment of thrombocytopenia. It is currently
being evaluated in phase II trials in patients with chemotherapy-
induced thrombocytopenia and chronic hepatitis C-related
thrombocytopenia and phase III trials in patients with idiopathic
(immune) thrombocytopenic purpura (ITP). The objective of this
review is to evaluate the emerging evidence for the potential use
of eltrombopag in the management of ITP in adults.
Methods
English language medical literature databases were searched for
appropriate articles related to the treatment of thrombocytopenia
with eltrombopag. The searches were conducted on October 27,
2005 or November 10–11, 2005 using the search terms
“Eltrombopag OR SB-497115 OR SB-497115-GR.” Further
searches were conducted on December 15, 2005. The cut-off
date was from the beginning of the database to the date of the
search unless otherwise stated. 
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fgci
• EMBASE, http://datastarweb.com
• BIOSIS, http://datastarweb.com
• Database of Abstracts of Reviews of Effects (DARE),
http://www.york.ac.uk/inst/crd/darehp.htm
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm
• Clinical Evidence, http://www.clinicalevidence.com
• http://www.clinicaltrials.gov
• http://www.clinicalstudyresults.org. Search strategy “GSK AND
Thrombocytopenia – chemotherapy induced OR immune
thrombocytopenic purpura”
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• National Guideline Clearing House, http://www.guideline.gov.
Search strategy “thrombocytopenia”
No articles or systemic reviews were identified. ClinicalTrials.gov
identified three ongoing phase II clinical trials. No treatment
guidelines involving eltrombopag were identified. Guidelines for
ITP were identified from the websites of the American Society of
Hematology (ASH) and the British Society for Haematology (BSH). 
Online abstracts from the following congresses were searched
using the search strategy “Eltrombopag OR SB-497115 OR SB-
497115-GR.”
• ASH, all conferences from 2002 to 2005, 
http://www.abstracts2view.com/hem_ash05atlanta/
http://www.abstracts2view.com/hem_sandiego2004/
http://www.abstracts2view.com/hem/
http://www.abstracts2view.com/hemphiladelphia02/
• European Hematology Association, all conferences from 2004
to 2005,
http://www.eurocongres.com/eha2005/abstracts.htm
http://eurocongres.com/eha2004/eha_scientific.html
Eltrombopag is currently in phase III development. Therefore, the
availability of clinical data for eltrombopag is limited. A total of six
abstracts were identified, of which five reported on the outcomes
of preclinical studies in animals or in-vitro studies, and one on
clinical data from healthy volunteers (Table 1). Phase II data,
which was presented at a symposium at the 47th Annual Meeting
of ASH (2005), but otherwise unpublished, was identified by a
news report and also included. 
Disease overview
ITP is a disorder in which the host’s immune system destroys
platelets. The pathogenesis of ITP remains to be full elucidated. It
has been proposed that it is an autoimmune disorder in which
autoantibodies play a major role by binding to platelet antigens
causing their premature destruction by the reticuloendothelial
system, in particular the spleen (Woods et al. 1984 a,b) (Fig. 1).
Recent evidence suggests that platelets are also destroyed by
cytotoxic T cells (Olsson et al. 2003). If bone marrow
megakaryocytes are not able to increase production and maintain
a normal number of circulating platelets, persistent
thrombocytopenia (decreased number of circulating platelets)
develops. Individuals who suffer from ITP may have symptoms
such as easy bruising on skin and gums, purpura, nosebleeds, or
mucosal bleeding. The most serious risk in patients who develop
ITP is intracranial hemorrhage.
Eltrombopag | emerging therapy review
© 2006 Core Medical Publishing Limited 222
Category Number of records
Full papers Abstracts
Initial search 0 6
records excluded 0 0
records included 0 6
Level 2 clinical evidence (RCT) 0 1
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review (preclinical
and phase I only)223
Most autoantibodies are directed against epitopes on the platelet-
surface antigen glycoprotein IIb/IIIa. Antibody-coated platelets
bind to antigen-presenting cells (macrophages) through Fc
receptors and are then internalized and degraded (Cines &
Blanchette 2002).
There are limited data on the incidence and prevalence of ITP
due to a lack of large sample studies. The Platelet Disorder
Support Association (PDSA) estimates that there are
approximately 20 000 individuals with ITP in the USA alone
(PDSA 2005). It is estimated that there are around 100 new
cases of ITP per million people each year in the USA, and about
half of those affected are children (PDSA 2005). In adults, this
disease is more common in women than men (Stasi & Provan
2004; Table 2). It was initially suggested that ITP affects
approximately three times more women than men, and that
these women were generally aged 20–40 years (Waters 1992).
However, more recent studies in Denmark and the UK have
suggested that the female–male ratio was 1.7 and 1.2,
respectively (Frederiksen & Schmidt 1999; Neylon et al. 2003). In
addition, these studies showed that the incidence of ITP was
greatest in adults older than 60 years. 
The acute and abrupt onset of ITP in children often follows a viral
illness (e.g. rubella, mumps, upper respiratory tract infection) or
immunization (Stasi & Provan 2004). In children, the prevalence is
the same among boys and girls and is most prevalent in children
aged 2–6 years. The majority of cases do not require treatment
and the disorder usually resolves within 2 to 8 weeks in 80–90%
of cases (Dickerhoff & von Ruecker 2000; Kuhne et al. 2001). In
contrast, the onset of ITP in adults is insidious and has a chronic
course (Table 2). 
There are limited studies assessing the morbidity and mortality
associated with ITP. It has been shown that ITP has a stable and
benign course in adults with mild and asymptomatic
thrombocytopenia, and that fewer than 10% of patients develop
severe thrombocytopenia that requires treatment (Stasi et al.
1995). Hemorrhage is the primary cause of long-term morbidity
and mortality in patients with ITP. Data from 1817 patients with
ITP showed that the rate of fatal hemorrhage was between 0.0162
and 0.0389 cases per patient-year at risk (Cohen et al. 2000). This
risk of fatal bleeding was greater in patients older than 60 years
(0.130 cases per patient-year) compared with patients younger
than 40 years (0.004 cases per patient-year). Predicted 5-year
mortality rates were also greater for patients older than 60 years
compared with patients younger than 40 years (47.8 vs 2.2%)
(Cohen et al. 2000).
Portielje et al. (2001) also reported that most adult patients with
ITP have a good outcome with infrequent hospital admissions and
no excess mortality compared with the general population.
However, patients with severe thrombocytopenia who did not
respond to therapy within the first 2 years (persistent low platelet
count below 30 x 109/L) had a four-fold increased mortality
compared with the general population (Portielje et al. 2001). 
There are no published clinical trials reporting the impact of ITP
on the quality of life of patients. However, frequent bruising and
bleeding episodes (e.g. nosebleeds that are difficult to stop and
bleeding gums during normal dental care), that are symptomatic
of ITP symptoms, are often distressing to the patient and their
families. In addition, these bleeding episodes are inconvenient
(e.g. removing blood stains from clothes), and may disrupt the
patient’s lifestyle by preventing them from partaking in everyday
activities. ITP is often accompanied by fatigue and muscle aches
which also impact on the patient’s quality of life, especially those
patients who normally lead an active lifestyle. Some patients with
ITP also report being depressed. This depression may be caused
by a lack of platelets which carry the neurotransmitter serotonin
to the brain (PDSA 2005). 
Current therapy options
The goal of treatment is to achieve a safe platelet count to prevent
major bleeding, while minimizing the adverse effects of the
therapy. The ultimate goal of therapy is spontaneous or
treatment-induced remission. Currently there are no evidence-
based guidelines for the management of thrombocytopenia and
limited data are available regarding the relative risks and benefits
of various treatment options. 
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Children Adults
Peak age incidence (years) 2–6 >50
Sex incidence (M : F) 1 : 1 1 : 1.7
Onset Acute Insidious
Preceding infection Common Unusual
Usual duration 2–4 weeks Years
Clinical course (%)
spontaneous remissions >80 2
chronic disease 24 43
Table 2 | Characteristics of immune thrombocytopenic purpura
in children and adults (adapted with permission from
Stasi & Provan. Mayo Clin Proc. 2004;79:504–522)
Platelet
Glycoprotein
IIb/IIIa 
Autoantibody
Macrophage
Fc 
receptor
Corticosteroids, intravenous immunoglobulin, 
anti-D immunoglobulin, danazol, vinka alkaloids 
Impair clearance of antibody-coated platelets
Fig. 1 | Pathogenesis of idiopathic (immune) thrombocytopenic
purpuraEltrombopag | emerging therapy review
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Therapy  Mechanism of action  Dosage and
administration
Response Duration of treatment
or response
Adverse
effects/disadvantages
First line
Oral corticosteroids –
prednisone
Not fully elucidated 
Increase platelet count
by impairing ability of
macrophages within
bone marrow to destroy
platelets and decreasing
synthesis of
autoantibodies has been
proposed (Gernsheimer
et al. 1989; Fujisawa et
al. 1993)
Oral (1 mg/kg per day) Approximately two-thirds
of patients achieve a
complete or partial
response within the first
few wks of treatment
(Cines & Blanchette
2002; Stasi & Provan
2004)
No consensus
Once platelet count
normalizes, prednisone
tapered off over
approximately 4 wks
(BCSH 2003; Stasi &
Provan 2004). Long-term
remission in 10–20% of
patients (Ben-Yehuda et
al. 1994; Stasi et al.
1995)
Acute adverse events
include hypertension,
hyperglycemia,
activation of
tuberculosis, systemic
fungal infection, or acute
psychosis
Long-term use
associated with
osteoporosis and
manifestations of
hypercortisolism (i.e.
Cushing syndrome,
facial swelling, acne,
cataracts, weight gain)
Intravenous
immunoglobulin (IVIg)a
Not fully elucidated 
Presence of antiidiotype
antibodies in IVIg block
Fc receptors on
macrophages,
preventing them from
binding to platelets has
been proposed
Slow (several hours)
intravenous 1 g/kg per
day for 2–3 consecutive
days 
Approximately 75% of
patients respond (Stasi &
Provan 2004)
Sustained remission is
infrequent, lasting no
longer than 3–4 wks
Postinfusion headache –
occasionally severe and
associated with nausea
and vomiting
Rare occurrence of renal
failure and pulmonary
insufficiency
Anaphylaxis in recipients
with congenital
deficiency of IgA
Expensive
Slow infusion
Anti-D immunoglobulinb Induces immune red
blood cell hemolysis,
causing decreased
function of mononuclear
macrophages,
preventing splenic
destruction of platelets
Single intravenous
infusion (50 mg/kg)
Approximately 70% of
patients respond (Stasi &
Provan 2004)
Fever/chill reactions
Lacks efficacy in Rh
D-negative and
splenectomized patients
Hemolytic anemia
Second line
Splenectomy  Removal of spleen which
is the site of platelet
destruction and
autoantibody synthesis
Surgical procedure Approximately two-thirds
of patients have a
sustained response to
splenectomy and
10–15% have a partial
response (George et al.
1996; Cines &
Blanchette 2002; BCSH
2003; Kojouri et al. 2004)
Approximately 75%
achieve complete
remission
2 case studies (7-year
follow-up) demonstrated
relapse (Fabris et al.
2001; Schwartz et al.
2003)
Bell (2000) suggested
that relapse may occur
in most patients if the
follow-up period is
sufficiently long e.g.
>7 years 
Lifelong reduced natural
defence against acute
bacterial infections (e.g.
sepsis). Risk of fatal
infection attributed to
absence of a spleen
estimated to be 0.73 per
1000 patient-years
(Schilling 1995)
26% of patients had
postoperative
complications (e.g.
pulmonary embolism)
resulting in prolonged
hospitalization or
readmission (Portielje et
al. 2001)
aUsed to treat internal bleeding when platelet count remains <5 x 109/L despite treatment with corticosteroids or when extensive purpura are present.
bFor Rh D-positive patients only. 
d, day; Rh, rhesus; IgA, immunoglobulin A; wk, week.
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Current guidelines for ITP
It is well established that current treatment guidelines for ITP
from ASH (George et al. 1996; ASH 1997; George & Davidoff
1997) and the BSH (BCSH 2003) are based on expert opinion
rather than evidence because of a lack of high-quality clinical
trials and long-term outcome data. Due to the lack of evidence-
based guidelines, Stasi and Provan (2004), Cines and Bussel
(2005), and Chong and Ho (2005) have also published their
opinions on the management of ITP based upon literature
reviews and their clinical experience. Although these guidelines
discuss recommendations for the management of ITP in adults,
children, and during pregnancy, this review will focus on the
guidelines for ITP in adults.
In adults, it is unusual for ITP to spontaneously remit. Therefore,
in cases of ITP associated with a high risk of bleeding, treatment
to increase platelet counts should be started. Adults with platelet
counts <30 x 109/L are likely to have significant purpura and some
mucosal bleeding. Therefore, BSH guidelines do not recommend
treatment in patients with platelet counts >30 x 109/L unless they
are undergoing a procedure which is likely to result in blood loss
(i.e. surgery or operative dentistry). In comparison, ASH guidelines
recommend treatment in patients with platelet counts <20 to 30 x
109/L (sic), or those with counts <50 x 109/L and significant
mucous membrane bleeding or risk factors for bleeding (e.g.
hypertension, peptic ulcer disease) (George et al. 1996; ASH
1997). The patient’s lifestyle should also be taken into
consideration when planning therapy.
Currently, there are three treatment options which are commonly
used for initial therapy of ITP; prednisone, intravenous
immunoglobulin (IVIg), and anti-D immunoglobulin (Table 3).
Splenectomy is a common second-line option. The most
convenient and inexpensive option is prednisone. No difference
has been demonstrated between these three treatment options
in terms of response rate, duration of response or the
requirement for a splenectomy at 1 year (Jacobs et al. 1994;
George et al. 2003). None of these treatments are particularly
effective; for example in patients treated with prednisone, fewer
than 10% have a sustained normal platelet response (Stasi et al.
1995). High-dose dexamethasone (40 mg per day for
4 consecutive days) has also been investigated as an initial
therapy for adults with ITP (Cheng et al. 2003). The data from
this study are promising. Eighty-five percent of patients
responded to high-dose dexamethasone, and approximately 42%
had a sustained response. 
Both the US and British guidelines recommend initial treatment
for ITP with oral prednisone (1 mg/kg per day) or oral prednisone
in combination with IVIg, dependent upon the platelet count and
the presence of bleeding. Alternatively, anti-D immunoglobulin
may be used instead of IVIg. However, it is only effective in rhesus
(Rh) D-positive patients. Neither of these treatments have been
shown to provide long-term remission of ITP. Stasi and Provan
(2004) remarked that a “wait-and-see” policy may be preferable in
patients without bleeding symptoms to avoid the long-term
toxicities associated with treatment. Adults with platelet counts
<5 x 109/L are at high risk of serious hemorrhage and it is
recommended that they are treated with intravenous
methylprednisolone 1 g/day for 3 days and either anti-D
immunoglobulin or IVIg.
If the patient fails to maintain a safe platelet count with
prednisone, intravenous anti-D immunoglobulin, and/or IVIg after
3–6 months, both the US and British guidelines recommend a
splenectomy as a second-line treatment option, which is
associated with a high risk of postoperative complications
(Table 3). An alternative to an open splenectomy is a laparoscopic
splenectomy which has a quicker recovery and reduced length of
hospitalization (Park et al. 2000). Mortality rates for open and
laparoscopic splenectomy are 1.0 and 0.2%, respectively (Kojouri
et al. 2004). Splenectomy-sparing strategies, including rituximab
or danazol, are considered by Cines and Bussel (2005) to defer or
avoid the need for splenectomy. 
A retrospective analysis of 139 patients with ITP has reported that
the age of the patient affects the response to, and adverse effects
of, therapy with corticosteroids, splenectomy, and danazol
(Andrés et al. 2003). Patients aged ≥60 years reported a higher
incidence of adverse events with corticosteroids, and a lower
success rate of splenectomy with more frequent postoperative
complications compared with patients aged <60 years. In
contrast, patients aged ≥60 years had a greater response rate to
danazol treatment.
Chronic refractory ITP
Approximately 11–35% of adults with ITP are refractory to
conventional treatment (BCSH 2003). These patients are at the
greatest risk of death (Portielje et al. 2001). ASH (1997), BSH
(BCSH 2003), Stasi and Provan (2004), and Cines and Bussel
(2005) recommend several treatment options for chronic
refractory ITP (often following a splenectomy), although there is
no consensus regarding preferred regimens and the majority often
have serious, toxic side effects (Table 4). The therapies most
commonly recommended by ASH, dependent on platelet count
and the presence of bleeding symptoms, included IVIg, accessory
splenectomy, high-dose corticosteroids, danazol, and
azathioprine (ASH 1997). 
Unmet needs
As stated previously, current guidelines for the treatment of ITP
are generally based on personal opinion rather than clinical
evidence. Therefore, to improve the management of ITP there is
a need for clinical trials with well-defined outcomes to assist with
the development of evidence-based treatment guidelines.
Important outcome measures may include platelet count,
frequency and severity of bleeding episodes, mortality from
bleeding, duration of response, safety and tolerability, quality of
life, and cost effectiveness. In addition, there is limited published
evidence of the cost effectiveness of current therapy options for
ITP. Despite this lack of data, it is evident from existing studies
that there is an unmet need for safe and well-tolerated therapies
that provide a sustained platelet response. 
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treatment with corticosteroids and IVIg. However, in many
patients the increase in platelet count is not sustained and they
require further treatment. Although corticosteroids are
inexpensive and are administered orally, their long-term use is
associated with adverse effects such as Cushing syndrome and
osteoporosis. In comparison, the use of IVIg is expensive and the
time taken for intravenous administration is inconvenient. Anti-D
immunoglobulin is less expensive than IVIg and is more
convenient to administer because it has a shorter infusion time.
However, approximately 16% of the general population are Rh D-
negative, and anti-D immunoglobulin is ineffective in this
population (National Blood Service 2006). Therefore, splenectomy
is generally indicated as a second-line treatment option for those
patients failing first-line therapy. Due to the frequent burden of
postoperative complications, both to the patient and healthcare
systems, and the risk of mortality associated with this treatment,
alternative options are required.
In addition to the need for alternatives to splenectomy, there is
also a need for safe and effective options for those patients who
relapse following a splenectomy (i.e. chronic refractory ITP).
Current therapies recommended for chronic refractory ITP are
limited. There is no consensus on their use and the majority of
treatments are potentially toxic with a low probability of a
sustained response (Chong & Ho 2005). Stasi and Provan (2004)
highlighted that the treatment of ITP is almost as dangerous as
the disease itself due to the similar number of deaths resulting
from treatment-related infections compared with hemorrhages.
The symptoms of ITP and the adverse events associated with its
treatment may impact on the quality of life of the patient. There is a
lack of data for quality of life outcomes in patients with ITP so the
effect of current treatment on this outcome remains to be
established. Results from an ITP Support Association questionnaire
completed by 171 patients with ITP showed that more than 50% of
individuals have a fear of bleeding and found the treatment side
effects difficult to live with (Watson & Bolton-Maggs 2000). Many
individuals feared the side effects of corticosteroids and the risk of
sepsis with splenectomy. In particular, adolescents were concerned
about the restrictions imposed on their lifestyle. 
New therapies in development 
A number of novel treatment options for thrombocytopenia are
currently in development (Table 5). Many of the current therapy
options for ITP act by reducing platelet destruction. However,
inadequate platelet production is also a contributing factor to
thrombocytopenia and has been observed in up to two-thirds of
patients with ITP (Stoll et al. 1985; Heyns Adu et al. 1986; Ballem et
al. 1987). Aledort et al. (2004) suggested that this inadequate platelet
production may occur as a result of accelerated endogenous
thrombopoietin (eTPO) clearance and that eTPO replacement
therapy may be a potential therapy for the management of ITP. 
Thrombopoietin is a cytokine responsible for regulating
megakaryopoiesis and the production of platelets. Binding of
thrombopoietin to its receptor (Mpl) induces the formation of a
Mpl dimer and tyrosine phosphorylation, resulting in the
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Table 4 | Adverse effects of current first- and second-line therapy options for chronic refractory immune thrombocytopenic
purpura (adapted with permission from Stasi & Provan. Mayo Clin Proc. 2004;79:504–522)
Adverse effects 
First line
Rituximaba First-infusion reactions
High-dose corticosteroids (methylprednisolone; oral or i.v. dexamethasone) Diabetes, fluid retention (methylprednisolone), osteoporosis, psychosis,
avascular necrosis of femoral head (dexamethasone)
Danazola Weight gain, hirsutism, liver function disturbances
Immunosuppressive agents (including azathioprinea and i.v.
cyclophosphamideb)
Immunosuppression, neutropenia, liver function disturbances (azathioprine),
leukemia, cytopenia, teratogenicity (i.v. cyclophosphamide)
Vinca alkaloids Neuropathy
Combination chemotherapyc Leukemia, cytopenia, teratogenicity
Dapsone Hemolysis, nausea, abdominal pain
Cyclosporinb Nephrotoxicity, immunosuppression
Second line
Campeth-1H Rigors, fever, lymphopenia
aConsidered a first-line therapy in patients failing splenectomy (Cines & Bussel 2005), and in the USA it may be considered instead of splenectomy in patients failing initial treatment with
steroids (George JN, personal communication 2006).
bConsidered a second-line therapy in patients failing splenectomy (Cines & Bussel 2005).
cConsidered a third-line therapy in patients failing splenectomy (Cines & Bussel 2005).
i.v., intravenous.227
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Therapy  Manufacturer Phase Mechanism of action
Eltrombopag GlaxoSmithKline Phase III Low molecular weight, nonpeptidyl thrombopoietin receptor agonist
(Luengo et al. 2004)
AMG531 Amgen Phase III Recombinant protein with action similar to that of endogenous
thrombopoietin. Stimulates the growth and maturation of megakaryocytes by
action on the Mpl receptor, resulting in an increase in platelet production
(Broudy & Lin 2004)
VB22B
(“minibody” agonist antibody)
Chugai  Preclinical Dimeric covalent antibody fragment, induces dimerization of the
thrombopoietin receptor (Orita et al. 2005)
Table 5 | Novel treatment options being developed for thrombocytopenia
phosphorylation and activation of numerous signaling molecules,
including those of the Janus Kinase (JAK) and signal transducers
and activators of transcription (STAT) pathway, the mitogen-
activated protein kinase (MAPK) pathway, and the
phosphoinositide 3-kinase (PI3K) pathway (Ezumi et al. 1995;
Geddis et al. 2002). This series of signaling pathways ultimately
leads to the stimulation of megakaryocyte development and the
production of platelets. However, the complete signal transduction
pathway of thrombopoietin has not been fully elucidated.
Several recombinant forms of human thrombopoietin have been
investigated, but many companies have abandoned clinical trials
with these agents due to the risk of immunogenicity and the need
for prolonged administration over 2–3 weeks (Anon. 2005a). 
AMG531 
Results from two phase II studies have reported that AMG531
administered by subcutaneous injection once a week or once a
fortnight significantly increased platelet counts, and was safe and
generally well tolerated (Kuter et al. 2004; Newland et al. 2004;
Stepan et al. 2005). However, a number of patients have
experienced serious adverse events with AMG531 including bone
pain and diffuse reticulin formation in the bone marrow reported
as myelofibrosis (Bussel et al. 2005; Stepan et al. 2005). The
response to treatment was highly variable between patients which
may suggest that individual dose adjustment may be required to
achieve the desired outcome (Kuter et al. 2004). 
Drug review
Eltrombopag is an agonist of the thrombopoietin receptor (Mpl)
currently in development for the treatment of ITP. The discovery of
eltrombopag from a library of 260 000 small molecule
compounds, based upon activation of STATs in BAF-3/TPO-R
cells, is discussed elsewhere (Luengo et al. 2004). 
Specificity
Preclinical evidence
In-vitro studies of human bone marrow cells have shown that
eltrombopag demonstrated a lack of activity in cell lines that did
not express the thrombopoietin receptor (Erickson-Miller et al.
2004a; Table 6). Furthermore, this agonist has demonstrated
species specificity in vitro and only activates signaling pathways in
human and chimpanzee platelets (Erickson-Miller et al. 2004b;
Table 6). Data from sequencing studies suggested that
thrombopoietin receptor agonists interact with the histine 499 and
threonine 496 residues to either change the conformation of the
receptor or induce dimerization, resulting in activation of the signal
transduction pathways of the thrombopoietin receptor (Erickson-
Miller et al. 2004b). The species specificity was confirmed in vivo
by the lack of effect of eltrombopag on platelet count in rats and
dogs, in contrast to chimpanzees (Sellers et al. 2004).
Increased platelet count 
Preclinical evidence – in vitro and in vivo
Preliminary in-vitro  data showed that eltrombopag demonstrated
maximal efficacy of thrombopoietin both in the proliferation of BAF-
3/TPO-R cells (EC50 = 30 nM) and an increase in the number of CD4+
cells, a marker of megakaryocyte differentiation, in human bone
marrow cell cultures (EC50 = 100 nM) (Luengo et al. 2004). In addition,
the proliferative response of eltrombopag was assayed by thymidine
incorporation in the human thrombopoietin cell line UT7-TPO and an
EC50 of 30 nM was demonstrated (Erickson-Miller et al. 2004a). In-
vitro studies comparing the biologic activity of eltrombopag with
thrombopoietin are detailed in Table 7 (Erickson-Miller et al. 2004a). 
The in-vivo activity of eltrombopag was initially demonstrated in
chimpanzees (Sellers et al. 2004). There was a 1.3- to 2.4-fold
increase in platelet count in three chimpanzees following five daily
doses of eltrombopag (10 mg/kg per day). Subsequently, the
ability of eltrombopag to activate the human thrombopoietin
receptor was confirmed by phase I clinical trials. 
Phase I clinical data 
Data from a randomized, single-blind, placebo-controlled study in
72 healthy male volunteers showed that eltrombopag, administered
as oral capsules once daily, for 1 day and after a 1 week washout
for 10 days increased platelet counts in a dose-dependent manner
at oral doses of 30 mg and above (Jenkins et al. 2004; Table 8).
Safety and tolerability
Data from  in-vitro studies with platelets obtained from human
volunteers showed that eltrombopag does not induce plateletactivation or enhance agonist-induced platelet aggregation
(Erhardt et al. 2004). 
In-vivo eltrombopag was well tolerated in chimpanzees, rats, and
dogs at all doses tested (Sellers et al. 2004). Phase I data in
healthy volunteers have shown that eltrombopag was well
tolerated over a 16-day period with no serious adverse events
reported. In addition, there were no significant changes in
laboratory or cardiovascular safety parameters (Jenkins et al.
2004). The majority of adverse events were reported to be mild in
intensity and self-limiting (no further details reported). 
Phase II clinical data 
Preliminary data from a randomized, double-blind, phase II study
in 104 adult patients with ITP (platelet count <30 x 109/L), who
had failed one prior therapy, demonstrated that eltrombopag (50
or 75 mg) once daily for 6 weeks significantly increased and
maintained platelet counts (>50 x 109/L) compared with placebo
(P<0.001) (Anon. 2005b). Of these responders, 87% achieved a
platelet counts >50 x 109/L by day 15. Eltrombopag was well
tolerated throughout the study.
Three ongoing phase II trials are currently determining the efficacy
and safety of eltrombopag in adults with chronic hepatitis C-
related thrombocytopenia, cancer patients receiving multiple
cycles of chemotherapy, and adults with refractory ITP.
Resource utilization
At this stage in its development, there is no evidence on which to
base an assessment of the impact of eltrombopag on resource
utilization in the management of ITP, although there are some
areas where it could offer an advantage. 
Corticosteroids are inexpensive. Therefore, it is likely that they will
continue to be used as an initial therapy option for short-term
treatment of ITP, despite tolerability issues. Alternative therapies,
IVIg and anti-D immunoglobulin, which may be used as first- or
second-line therapies, are relatively expensive to produce, and
IVIg is inconvenient to administer. Eltrombopag may potentially
have resource utilization benefits as a result of better tolerability
than corticosteroids, and a lower cost of production and easier
route of administration than IVIg and anti-D immunoglobulin.
Existing therapies have a different mode of action to
eltrombopag. Corticosteroids, IVIg, and anti-D immunoglobulin
act to prevent platelet destruction, whereas eltrombopag
increases platelet production. Therefore, eltrombopag may
potentially be used alone or in combination with these agents to
increase the rate of remission and avoid the need for a
splenectomy. It is expected that avoiding the requirement for
hospitalization and the potential complications and risk of
mortality associated with a splenectomy would be of benefit to
the patient and healthcare systems. 
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Method Results
Receptor selectivity
Panel of transfected and nontransfected cell lines in which other cytokines were
active (G-CSF, Epo, IL-3, interferon-alfa, or interferon-gamma)
In those cell lines that did not express the thrombopoietin receptor,
eltrombopag was inactive over a three-fold concentration range in proliferation,
receptor gene, or STAT activation assays
Species specificity
Electrophoretic mobility shift assay No signaling in response to eltrombopag detected using platelets of
cynomolgus macaques, cat, mouse, rat, pig, ferret, or tree shrew
HepG2 cells transiently infected with human thrombopoietin receptor, murine, or
cynomolgus monkey receptor
Only cells transfected with human thrombopoietin receptor had STAT-activated
reporter gene activity
Sequencing of thrombopoietin transmembrane domains of mice, dogs,
and ferrets
In mice, dogs, and ferrets, thrombopoietin receptor contains Leu 499
Human and chimpanzee thrombopoietin receptor contains His 499
Point mutation replacing Leu with His 499 in thrombopoietin receptor of
cynomolgus macaques
Conferred thrombopoietin receptor activity
Point mutation replacing His with Leu 499 in transmembrane domain of human
thrombopoietin receptor
Inactive thrombopoietin receptor
HepG2 cells transiently infected with mutated murine G-CSF receptor (point
mutation corresponding to His 499)
Conferred thrombopoietin receptor activity
HepG2 cells transiently infected with mutated murine G-CSF receptor (double
point mutation corresponding to His 499 and Thr 496)
Conferred thrombopoietin receptor activity
Epo, epoetin; G-CSF, granulocyte colony-stimulating factor; His, histine; IL-3, interleukin-3; Leu, leucine; STAT, signal transducers and activators of transcription; Thr, threonine.
Table 6 | Selectivity and specificity of eltrombopag in vitro (Erickson-Miller et al. 2004a,b)229
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Oral dose of eltrombopag (mg) Mean platelet count at
baseline/day 1 (platelets/uL)
Maximum mean platelet count at
day 14 or 16 (platelets/uL)
Mean increase from baseline
(platelets/uL)
Placebo 234 000 255 000 21 000
5 217 000 249 000 32 000
10 251 000 291 000 40 000
20 236 000 279 000 43 000
30 249 000 323 000 74 000
50 254 000 356 000 102 000
75 239 000 357 000 118 000
Table 8 | The dose-dependent effect of eltrombopag on mean platelet count in 72 healthy male volunteers (Jenkins et al. 2004)
Method Results
Western blot analysis for activation of STAT and MAPK pathways using
phospho-specific antibodies on lysates of UT7-TPO cells (a thrombopoietin-
dependent, megakaryocytic cell line) treated with eltrombopag
Kinetics and level of induction of pathway phosphorylation events with
eltrombopag similar to that seen with thrombopoietin
mRNA expression of several early response genes associated with proliferation
and thrombopoietin activation (i.e. Fos, EGR-1, and thyroid-like receptor 3) were
measured in response to eltrombopag treatment
Kinetics and level of induction of gene expression with eltrombopag similar to
that seen with thrombopoietin
Differentiation of normal human bone marrow progenitors (CD34) into
CD41+ cells of the megakaryocyte lineage
Eltrombopag activity equal to or better than recombinant thrombopoietin
(EC50 = 100 nM)
EC50, the molar concentration of an agonist, which produces 50% of the maximum possible response for that agonist; EGR-1, early growth response-1; MAPK, mitogen-activated protein
kinase; mRNA, messenger ribonucleic acid; STAT, signal transducers and activators of transcription.
There are very limited data regarding the economic burden of a
splenectomy and the resulting complications on healthcare
resources. An economic model with a theoretical cohort of
100 patients was developed to predict the cost of treating ITP
patients with anti-D immunoglobulin for 1 year versus an immediate
splenectomy (Bennett et al. 2000). The cost of a splenectomy was
estimated to be $US16 000 compared with $US1213 per anti-D
infusion. This predictive cost analysis suggested that a minimum of
47 patients would need to avoid a splenectomy with anti-D
immunoglobulin to result in a cost saving. Therefore, it may also be
expected that avoidance of splenectomy with eltrombopag would
have a beneficial effect on the cost of treatment. 
Eltrombopag may also have utility in patients with chronic
refractory ITP who have failed a splenectomy. Compared with
currently recommended therapies which are associated with toxic
effects, eltrombopag is expected to be a safer alternative. 
Drug profile
Eltrombopag is in the early stages of clinical development, and
phase I and phase II data reported so far are encouraging. 
In-vitro and  in-vivo data have demonstrated the species
specificity of eltrombopag and its selectivity for the
thrombopoietin receptor. Results from phase I studies in healthy
volunteers showed that eltrombopag ≥30 mg increased platelet
counts to clinically relevant levels (>30 x 109/L) and was generally
well tolerated. However, long-term data with clinically relevant
outcomes in patients with ITP are required to assess the duration
of response and long-term safety profile of eltrombopag. Current
evidence suggests that eltrombopag will be administered orally
once daily which would be an advantage over many of the
existing therapies. In order to determine eltrombopag’s place in
therapy, the outcomes of phase II and phase III trials are required
to determine its potential clinical impact. 
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